Dongwha Pharmaceutics Launches Prescription Drug 'Ecragel' for Axillary Hyperhidrosis

First Topical Prescription Treatment in Korea

Dongwha Pharmaceutics announced on January 19 that it has launched Ecragel, the first prescription topical treatment for primary axillary hyperhidrosis in Korea.

Ecragel. Dongwha Pharmaceutics

Ecragel is a gel-type formulation containing the active ingredient sofpironium bromide. It works by directly blocking the sweat secretion signals at the sweat glands. The treatment is effective with just one application per day. Developed as a twist-type container that dispenses a single dose with each twist, it offers convenience by allowing application without getting the product on the hands.

Ecragel is a new drug that was first launched in Japan by Kaken Pharmaceutical in 2020. The name combines 'ECC,' the first letters of 'eccrine' sweat glands, which are involved in body temperature regulation, and the word 'block.' It has a high binding affinity for muscarinic receptors in eccrine sweat glands and inhibits acetylcholine binding, thereby suppressing sweat secretion. Observational studies have shown rapid symptom improvement within one week, and long-term clinical results have demonstrated sustained efficacy for up to 52 weeks.

Dongwha Pharmaceutics signed an exclusive domestic supply agreement for Ecragel in June 2023 and secured the foundation for its domestic launch by obtaining product approval from the Ministry of Food and Drug Safety in August 2025.

Dongwha Pharmaceutics plans to use the launch of Ecragel as a starting point to raise awareness that primary axillary hyperhidrosis is a treatable condition. The company aims to lead the domestic hyperhidrosis treatment market by leveraging the mechanism and convenience of Ecragel, as well as synergy with Dryonac, a general over-the-counter hyperhidrosis treatment.

Primary axillary hyperhidrosis is a condition characterized by excessive sweating in the underarm area. Symptoms usually begin in childhood or adolescence and can result in emotional withdrawal and social isolation, ultimately diminishing quality of life. In Japan, the launch of Ecragel led to increased awareness, particularly among adolescents, and the market expanded significantly.

A representative from Dongwha Pharmaceutics stated, "Severe hyperhidrosis can cause not only discomfort in daily life but also emotional withdrawal, making active treatment essential. We hope that Ecragel, as the first prescription topical treatment for primary axillary hyperhidrosis in Korea, will quickly establish itself in the market and become an innovative treatment option that improves patients' quality of life."